Lantheus Holdings, Inc. LNTH
101.62 USD +0.61 (+0.60%)
At closeNov 10, 2026, 4:26 PM EST
101.62 0.00 0.00%
After hours · Nov 10, 4:26 PM ET
101.00 Day range 101.69
50.69 52-week range 111.86
- YTD
- +52.70%
- 1 year
- +100.47%
News
benzinga.com PharmaLogic Holdings Agrees To Acquire Lantheus Holdings' CDMO Operations, Springfield Production Site; Financial Terms Not Disclosed PharmaLogic Holdings Corp. ("PharmaLogic" or the "Company"), the only independent contract development and manufacturing organization (CDMO) of scale dedicated exclusively to radiopharmaceuticals,…
prnewswire.com PharmaLogic to Acquire Lantheus' CDMO Business and Springfield, New Jersey Manufacturing Facility Expands U.S. therapeutic manufacturing capacity and creates the first transatlantic CDMO platform with a proven commercial track record in radioligand therapies WALTHAM, Mass., Nov. 9, 2026…
benzinga.com Lantheus Holdings Q3 Adj. EPS $1.68 Beats $1.24 Estimate, Sales $389.913M Beat $359.757M Estimate Lantheus Holdings (NASDAQ:LNTH) reported quarterly earnings of $1.68 per share which beat the analyst consensus estimate of $1.24 by 35.48 percent. This is a 32.28 percent increase over earnings of…
globenewswire.com Lantheus Welcomes CMS CY27 Final Rule Advancing Access to Diagnostic Radiopharmaceuticals Final rule maintains separate payment for advanced diagnostic imaging agents and confirms PYLARIFY TruVu™ Transitional Pass-Through status through September 30, 2029; permanent HCPCS code A9613 now…
globenewswire.com Lantheus Reports Third Quarter 2026 Financial Results Worldwide revenue of $389.9 million in the third quarter of 2026 GAAP fully diluted earnings per share of $0.33, compared to $0.41 in the third quarter of 2025 Adjusted fully diluted earnings per…
globenewswire.com Lantheus Announces Presentation of Data at the 2026 Clinical Trials on Alzheimer's Disease Annual Meeting BEDFORD, Mass., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the Company) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight…
benzinga.com This Adobe Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday Analysts downgraded ACGL, ASTS, PS, LNTH and ADBE, cutting ratings and price targets; ASTS target fell to $54 and Adobe’s to $267.
benzinga.com Mizuho Downgrades Lantheus Holdings to Neutral, Lowers Price Target to $109 Mizuho analyst Anthony Petrone downgrades Lantheus Holdings (NASDAQ:LNTH) from Outperform to Neutral and lowers the price target from $115 to $109.
globenewswire.com BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Option Care Health, Inc. (Nasdaq – OPCH), Lantheus Holdings Inc. (Nasdaq – LNTH), MarketAxess Holdings Inc. (Nasdaq – MKTX), Sangoma Technologies Corporation (Nasdaq – SANG) BALA CYNWYD, Pa., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky…
defenseworld.net Lantheus Holdings, Inc. (NASDAQ:LNTH) Stock Rated “Hold” by Wall Street Analysts Shares of Lantheus Holdings, Inc. (NASDAQ: LNTH - Get Free Report) have received an average rating of "Hold" from the fourteen research firms that are covering the stock, Marketbeat.com reports. Ten…
benzinga.com Lantheus Receives Transitional Pass-Through Payment Status For PYLARIFY TruVu Injection From Centers For Medicare & Medicaid Services, Effective Oct. 1 Lantheus Holdings, Inc. ("Lantheus" or the "Company") (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver…
globenewswire.com Lantheus Announces CMS Grants Transitional Pass-Through Status for PYLARIFY® TruVu (piflufolastat F 18) Designation, together with a permanent HCPCS code effective October 1, 2026, supports patient access and reimbursement for PYLARIFY TruVu, Lantheus' PSMA PET imaging agent Designation, together with…
globenewswire.com BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: SoundThinking, Inc. (Nasdaq – SSTI), Lantheus Holdings Inc. (Nasdaq – LNTH), MarketAxess Holdings Inc. (Nasdaq – MKTX), Sangoma Technologies Corporation (Nasdaq – SANG) BALA CYNWYD, Pa., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky…
benzinga.com Lantheus Holdings Announces First Patient Dosed In SPARROW NCT07831824, Phase 2/3 Registrational Trial Evaluating LNTH-2401 Lantheus Holdings, Inc. ("Lantheus" or the "Company") (NASDAQ:LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver…
globenewswire.com Lantheus Announces First Patient Dosed in SPARROW Phase 2/3 Registrational Trial in Prostate Cancer Study advances development of Lantheus' investigational GRPR-targeted PET imaging program for prostate cancer Study advances development of Lantheus' investigational GRPR-targeted PET imaging program…
globenewswire.com BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Werewolf Therapeutics, Inc. (Nasdaq – HOWL), Beazer Homes USA, Inc. (NYSE – BZH), Lantheus Holdings Inc. (Nasdaq – LNTH), MarketAxess Holdings Inc. (Nasdaq – MKTX) BALA CYNWYD, Pa., Sept. 24, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky…
globenewswire.com Lantheus Receives Final FDA Approval for BRAVNETSA™ (Lutetium Lu 177 Dotatate), the Only Radiopharmaceutical FDA has Determined to be Bioequivalent and Therapeutically Equivalent to LUTATHERA® for the Treatment of GEP-NETs BEDFORD, Mass., Sept. 22, 2026 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. ("Lantheus" or the "Company") (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling…
prnewswire.com Are LNTH, ITGR, CZR Obtaining Fair Deals for their Shareholders? /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws
businesswire.com Lantheus Holdings Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Lantheus Holdings, Inc. - LNTH NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of…
gurufocus.com LNTH Stock Alert: Halper Sadeh LLC is Investigating Whether Lantheus Holdings, Inc. is Obtaining a Fair Price for its Shareholders Halper Sadeh LLC, an investor rights law firm, is investigating the sale of Lantheus Holdings, Inc. (NASDAQ: LNTH) to Curium US Holdings LLC for $102.50 per sha
businesswire.com LNTH Stock Alert: Halper Sadeh LLC is Investigating Whether Lantheus Holdings, Inc. is Obtaining a Fair Price for its Shareholders NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating the sale of Lantheus Holdings, Inc. (NASDAQ: LNTH) to Curium US Holdings LLC for $102.50 per share in cash,…
benzinga.com FDA Approves Lantheus Imaging Drug for Alzheimer's Diagnostics Lantheus receives FDA approval for PET imaging agent used to evaluate adults for Alzheimer's disease by identifying tau pathology.
reuters.com US FDA approves Lantheus' brain-imaging agent for Alzheimer's assessment The U.S. Food and Drug Administration has approved a radioactive agent from Lantheus Holdings for use in brain scans to help assess patients for Alzheimer's disease, the company said on Friday.- benzinga.com Lantheus Holdings Announces FDA Approval Of TAUKLARIFY, Radiodiagnostic Agent Indicated For PET Of Brain In Adults For Alzheimer’s Disease Lantheus Holdings, Inc. ("Lantheus" or the "Company") (NASDAQ:LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver…
globenewswire.com Lantheus Announces FDA Approval of TAUKLARIFY™ (Florquinitau F 18 Injection), an F18-Labeled Tau PET Imaging Agent for Alzheimer's Disease BEDFORD, Mass., Aug. 14, 2026 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus” or the “Company”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling…
gurufocus.com Are DSGR, LNTH, ATKR Obtaining Fair Deals for their Shareholders? Are DSGR, LNTH, ATKR Obtaining Fair Deals for their Shareholders? PR Newswire NEW YORK, Aug. 7, 2026
prnewswire.com Are DSGR, LNTH, ATKR Obtaining Fair Deals for their Shareholders? /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws
gurufocus.com Lantheus Holdings Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Lantheus Holdings, Inc. - LNTH Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of [url="]Kahn Swick and Foti[/url], LLC (âKSFâ) are investigating the propos- benzinga.com Lantheus Holdings Q2 Adj. EPS $1.55 Beats $1.30 Estimate, Sales $388.200M Beat $362.416M Estimate Lantheus Holdings (NASDAQ:LNTH) reported quarterly earnings of $1.55 per share which beat the analyst consensus estimate of $1.30 by 19.23 percent. This is a 1.27 percent decrease over earnings of…
- benzinga.com Truist Securities Downgrades Lantheus Holdings to Hold, Lowers Price Target to $102.5 Truist Securities analyst Richard Newitter downgrades Lantheus Holdings (NASDAQ:LNTH) from Buy to Hold and lowers the price target from $125 to $102.5.
benzinga.com TD Cowen Downgrades Lantheus Holdings to Hold, Lowers Price Target to $102.5 TD Cowen analyst Tara Bancroft downgrades Lantheus Holdings (NASDAQ:LNTH) from Buy to Hold and lowers the price target from $110 to $102.5.
benzinga.com Analyst Calls Curium's $8 Billion Lantheus Buyout An 'Excellent Outcome' For Shareholders CapVest-backed Curium agrees to acquire Lantheus for up to $8B, expanding its global footprint in nuclear medicine.
benzinga.com Under the Radar: 3 Boring Small Caps That Could Return 10x Investors spend an enormous amount of time searching for the next stock that can rise 10 times in value. They study disruptive technologies, enormous addressable markets, charismatic founders, and…- benzinga.com Mizuho Maintains Outperform on Lantheus Holdings, Lowers Price Target to $115 Mizuho analyst Anthony Petrone maintains Lantheus Holdings (NASDAQ:LNTH) with a Outperform and lowers the price target from $120 to $115.
benzinga.com Truist Securities Maintains Buy on Lantheus Holdings, Raises Price Target to $125 Truist Securities analyst Richard Newitter maintains Lantheus Holdings (NASDAQ:LNTH) with a Buy and raises the price target from $115 to $125.- benzinga.com Mizuho Maintains Market Outperform on Lantheus Holdings, Raises Price Target to $120 Mizuho analyst Anthony Petrone maintains Lantheus Holdings (NASDAQ:LNTH) with a Market Outperform and raises the price target from $115 to $120.
- benzinga.com B. Riley Securities Maintains Buy on Lantheus Holdings, Raises Price Target to $129 B. Riley Securities analyst Justin Walsh maintains Lantheus Holdings (NASDAQ:LNTH) with a Buy and raises the price target from $97 to $129.
benzinga.com FDA Manufacturing Issues Delay Lantheus' Tumor Imaging Kit Lantheus receives FDA Complete Response Letter for LNTH-2501. William Blair pushes Octevy sales outlook back by one year.
benzinga.com Citizens Reiterates Market Outperform on Lantheus Holdings, Maintains $115 Price Target Citizens analyst David Turkaly reiterates Lantheus Holdings (NASDAQ:LNTH) with a Market Outperform and maintains $115 price target.
benzinga.com Concentrix, AeroVironment And 3 Stocks To Watch Heading Into Monday U.S. stock futures up, watch Concentrix Corp, Lantheus Holdings, AeroVironment, Viridian Therapeutics, Universe Pharmaceuticals for earnings and news.- benzinga.com Lantheus Holdings Receives FDA Complete Response Letter For LNTH-2501 Due To Manufacturing Facility Issues; No Safety Or Efficacy Concerns Identified Lantheus Holdings, Inc. ("Lantheus" or "Company") (NASDAQ:LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better
- benzinga.com Mizuho Maintains Outperform on Lantheus Holdings, Raises Price Target to $115 Mizuho analyst Anthony Petrone maintains Lantheus Holdings (NASDAQ:LNTH) with a Outperform and raises the price target from $100 to $115.
benzinga.com 'Lantheus Weighs Potential $7 Billion Sale Following Offer From Curium' - Bloomberg News https://www.bloomberg.com/news/articles/2026-05-22/lantheus-is-said-to-weigh-sale-following-offer-from-curium- benzinga.com Truist Securities Reiterates Buy on Lantheus Holdings, Raises Price Target to $115 Truist Securities analyst Richard Newitter reiterates Lantheus Holdings (NASDAQ:LNTH) with a Buy and raises the price target from $98 to $115.
benzinga.com These Analysts Raise Their Forecasts On Lantheus After Upbeat Q1 Results Lantheus Holdings Inc (NASDAQ:LNTH) reported upbeat Q1 earnings, reaffirmed guidance, and received price target hikes from analysts.- benzinga.com Citizens Maintains Market Outperform on Lantheus Holdings, Raises Price Target to $115 Citizens analyst David Turkaly maintains Lantheus Holdings (NASDAQ:LNTH) with a Market Outperform and raises the price target from $85 to $115.
benzinga.com Airbnb To Rally Around 21%? Here Are 10 Top Analyst Forecasts For Friday Wall Street analysts changed outlook on top names. Includes upgrades/downgrades. Check analyst ratings page for details on MCD, NKE, ABNB, LNTH, XYZ, ASTH, RNG, CELH.- benzinga.com Mizuho Maintains Outperform on Lantheus Holdings, Raises Price Target to $100 Mizuho analyst Anthony Petrone maintains Lantheus Holdings (NASDAQ:LNTH) with a Outperform and raises the price target from $95 to $100.
benzinga.com Korn Ferry, Hewlett Packard Enterprise And 3 Stocks To Watch Heading Into Monday U.S. stock futures up, Korn Ferry, ZIM, Lantheus, HPE, and Caseys General Stores in focus for earnings. Check out premarket coverage.
benzinga.com Earnings Scheduled For February 26, 2026